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Inter&kin 1 (IL-l), present in high amounts in normal human skin without any sign of inflammation, suggests acomplex mechanism by which 
its bioactivity is regulated. The specific receptor antagonist of IL-1 (IL-lra) was analyzed in human skin, sweat and cultured keratinocytes. Extracts 
of both skin and cultured keratinocytes blocked the binding of [‘2sI]IL-1 to its receptor whereas sweat did not. The inhibitory activity was 
cell-associated, was not secrctcd by cultured keratinocytes, and IL-lra mRNA was identified in these cells. There was an inverse relationship between 
the level of IL-lra and that of IL-la andj3 since extracts of differentiating kerdtinocytes (DK) and higher IL-lra levels and expressed more mRNA 
for IL-lra than non-differentiated keratinocytcs (NDK), whereas NDK contained 4 times more IL-la and /? proteins than DK. This association 
of cell differentiation with a shift in agonist/antagonist ratio might be related to important autocrine or paracrine functions of IL-I in normal and 
inflamed human skin 
1. INTRODUCTION 
Keratinocyte; Human epidermis; Interleukin-1; Interleukin-1 receptor antagonist 
IL- 1 a and /!I are 17.5 kDa polypeptides which play an 
important role in immunological and inflammatory 
reactions as well as in the body’s response to microbial 
invasion [ 11. Initially described as a monocyte product, 
IL-l is synthetized by a wide variety of cells including 
keratinocytes [2,3]. High levels of biologically active 
IL-l were found in normal unstimulated human epider- 
mis and human sweat [4,5]. The functional and physio- 
logical relevance of this IL-1 pool is still unclear. Immu- 
nohistological studies suggest a link between epidermal 
IL-1 and the differentiation process of keratinocytes [6]. 
Cultured keratinocytes contain mRNA for both forms 
of IL- 1 but the functional activity both in cultured cells 
and normal human epidermis depends essentially on 
IL-1 a [7]. Translation of IL-lp mRNA as an inactive 
product (31 kDa IL-lp), which can not be cleaved to the 
mature form has been recently reported, and deficiency 
of a protease necessary to process IL-l/3 might be im- 
portant to avoid persistent inflammation [8]. However, 
high amounts of biologically active IL-la are also pre- 
sent in normal human epidermis after extraction and in 
sweat without any sign of inflammation. This suggests 
that IL-l activity in human epidermis might be regulat- 
ed by specific inhibitors. During the last few years in- 
terferences with IL-l biological activities have been de- 
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scribed [9]. A specific inhibitor of IL-l acting as recep- 
tor antagonist (IL-lra) has been originally isolated from 
the urine of patients with monocytic leukemia and in the 
supernatants of stimulated human monocyte cultures 
[ 10-121. In this study, we demonstrate the presence of 
IL-1 ra in normal human epidermis and in extracts of 
cultured human keratinocytes and show that the expres- 
sion of IL-lra is higher in more differentiated cells. In 
contrast, IL-lra was not detected in human sweat. 
2. MATERIALS AND METHODS 
2.1. Preparation of specimens and culture conditions 
Normal human skin was obtained from abdominal plastic surgery. 
The epidermis was separated from the dermis by heating whole skin 
for I min at 56°C in 0.9% sodium chloride as described [6]. Human 
sweat was collected from patients with spontaneous hand hyperhidro- 
sis as described [5]. Human keratinocytes from foreskin, obtained as 
described by Rheinwald and Green [13], were cultured in a mixture 
of Dulbecco-Vogt and Ham’s F12 (3:1) medium supplemented with 
10% fetal calf serum (FCS) (Seromed, Berlin, Germany), insulin (0.4 
&ml), adenine (24 ,@ml), transferrin (6 pg/ml), triiodothyronine (2 
ng/ml), and epidermal growth factor (10 ng/ml). Keratinocytes were 
grown in this medium at normal Ca” (1.3 mM) concentration until 
confluency (10 days) and then with low Ca*’ (0.03 mM) during the 
next 2 or 3 days. With this latter medium, the more differentiated cells 
(subsequently quoted as differentiating keratinocytes, DK) are released 
after gentle shaking and the less differentiated cells (subsequently 
quoted as non-differentiated keratinocytes, NDK) remain attached to 
the culture dish. Supernatants were collected by centrifugation and 
DK washed 3 times with phosphate-buffered saline (PBS) @H 7.2) 
before being stored at -70°C as dry pellet. NDK were washed 3 times 
with PBS by scraping with a rubber policeman in PBS containing 20 
PM EDTA and 5 PM iosoacetamide, and stored at -70°C until use. 
Human skin and keratinocytes were homogenized on ice 2 times for 
1 min using a polytron and sonicated 3 times for 15 sin PBS containing 
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20pM EDTA and 5pM iodoacetamide. After centrifugation at 10 000 
x g supernatants were used for total protein measurement (Lowry), 
IL-la and fi enzyme-immunoassay and IL-l binding assay. 
2.2. IL-la and IL-I/3 determination 
Content of IL-la and p in samples before and after IL-1 immuno- 
depletion was measured by enzyme-immunoassay (EIA) as previously 
described [14]. IL-I was removed by immunoaffinity gels specific to 
IL-la or IL-Ip according to the manufacturer’s method (Endogen Inc; 
Boston, MA). 
2.3. IL-lra delerminulion 
IL-lra was measured by receptor binding assay [I I] after depleting 
specimens of IL-la and IL-ID which can interfere with the determina- 
tion. Human recombinant IL-la (hrlL-la), radioiodinated by the 
chloramine T method (specific activity 3 to 5~10~ cpming), was used 
for binding to the murine thymoma sublinc EL4-6.1 as described 
elsewhere [1 1,151. Binding inhibition (%) was calculated as follows: 
l- /[(cpm in the presence of samples - cpm nonspecific binding)/(cpm 
of total binding - cpm non-specific binding)] x 1001. 
Total binding, non-specific and total radioactivity added were approx- 
imately 1080, 80 and IO 000 cpm, respectively. 
2.4. RNA extraction and Northern blot unalysis 
Cell pellets were frozen (-80°C) in 4.5 M guanidium thiocyanate 
and 0.2 M B-mercaptoethanol, and total RNA was purified as de- 
scribed previously [16]. Total RNA (10 pug) was denatured with 2% 
formaldehyde, electrophoresed on 1.2% agarose gel and stained with 
ethidium bromide (0.5 &ml) to asses RNA integrity. After transfer 
to a nylon membrane (Biodyne, Pall, Ultrafinc Filtration Carp, Glen- 
core, NY, USA), the filters were baked for 2 h at 80°C and prehybri- 
dized for 6 h at 58°C with 200 @cm’ of the hybridization mixture 
containing 50% (v/v) deionized formamide, 0.8 M NaC1, 2 mM 
EDTA, 0.1% SDS, 2.5 x Denhardt’s olution and lOO,@ml denatured 
salmon sperm. The filters were then hybridized overnight at 58°C with 
100 ,f.dlcm’ of fresh hybridization mixture containing the IL-la or 
IL+ RNA anti-sense probe labelled with 3ZP or with a 210-bp frag- 
ment of IL-lra DNA labelled by multi-priming system kit (Boehringer 
Mannheim, Germany) with [a-3’P]dATP. The hybridized membrane 
was washed to a stringency of 0.1 xSSC, 0. I % SDS for 30 min at 70°C. 
Membranes were exposed to Kodak XAR Film at -70°C for 24 h. The 
IL-la cDNA was a 1764-bp clone inserted into the Hind111 site of 
pUC8. A 500-bp fragment isolated between Ps/I-Hind111 was sub- 
cloned in pSP64. The IL-Q9 cDNA was a 1200 bp clone inserted in the 
Pstl site of pAT 153. A 570-bp fragment isolated between HindII- 
Hind111 was subcloned in pSP65. The probe used to detect he IL-1 ra 
mRNA was a 2lO-bp fragment coding for the COOH-terminal half of 
the protein and recognized the common region coding for sIL- 1 ra and 
icIL-lra (gift of S. Eisenberg, Synergen, Boulder) [17]. 
3. RESULTS 
3.1. Content of IL-la und p und Northern blot analysis 
of’IL-1 mRNA 
As previously described [5,8] a high level of IL- 1 a and 
low amount of IL-l/? were observed in extracts of nor- 
mal human epidermis and in sweat (Table I). In cultured 
keratinocytes, the amount of cell-associated IL-Ip was 
greater than in human skin extract (Table I). IL-l& and 
IL-lb levels in keratinocyte supernatants were below 
the limit of detection of the assay (~10 pg/ml). These 
data confirm that human epidermal cells contain a high 
level of IL-l (mainly IL-la), but secrete only little a- 
mounts of this cytokine [19]. Moreover, IL-la and B 
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concentrations depend upon the stage of cell differentia- 
tion, as 4 times more IL-ICY or/3 was found in NDK than 
in DK. This result contrasts with that of Mitzutani et 
al. [8] who observed comparable levels of IL-la and p 
in normal cultured keratinocytcs under standard (1.5 
mM) and low (0.15 mM) calcium concentrations. HOW- 
ever, these investigators used other culture conditions 
and immunoassays to evaluate both forms of IL-l. 
Northern blot analysis identified a stronger signal for 
IL-la mRNA in NDK as compared to DK (Fig. 1). The 
same observations applied to the steady-state level of 
IL-ID mRNA whose signal was however less intense 
than that of IL-la: mRNA. Therefore, these results are 
in accordance with the protein values showing more 
IL-l in NDK than in DK. 
3.2. Detection qf IL-lra biological uctivity 
To specifically measure IL-lra by the receptor bind- 
ing assay, each lysate was immuno-depleted of IL-la 
and p. The specific binding of [“51]IL-lcr to EL4-6.1 
cells was significantly inhibited (75%) by human epider- 
mis extract and by cultured human keratinocyte extract 
(84100%). The extraction buffer did not modify the 
binding assay (Table II). The amount of IL-la and ,B 
remaining in the extracts after depletion was less than 
the concentration of hrIL-la and hrIL-lp which affect 
the binding of [‘2”I]IL-la [20]. Contrary to monocytesi 
macrophages, keratinocytes do not appear to secrete 
IL-lra since we could not detect significant (~20%) in- 
hibition in the supernatants of cultured keratinocytes. 
The % inhibition obtained for the sample of sweat was 
also insignificant. 
3.3. Dose-response of IL-1 inhibitory activity in human 
epidermis, NDK and DK 
As shown in Table II, the inhibitor activity at l/20 
dilution was higher in DK (100%) than in NDK 
(84.1%). Dilution curves were performed on specimens 
depleted of IL-la and IL-lb showing that binding of 
[‘251]IL- 1 a was inhibited in a dose-dependent fashion by 
human epidermis, NDK and DK extracts (Fig. 2). 
Table 1 
Content of IL-la and p in epidermis, sweat and cultured human 
keratinocytes (EIA) 
Specimen IL-la 
(ng/mg prot.) 
IL-l/l 
(np/mg prot.) 
- 
Human epidermis extract 25.76 0.06 
Human sweat 10.43* 0.10* 
NDK extract 34.09 5.84 
DK extract 7.36 1.69 
Supernatant 0.16* <0.01* 
Human epidermis, sweat, extracts of non-differentiated keratinocytes 
(NDK) or differentiating keratinocytes (DK) and supernatants of 
cultured keratinocytes were analyzed for their content of IL-lu and 
IL-1B by EIA. Values are normalized to ng protein or ml*. 
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Fig. 1. IL-la, IL-I/? and IL-Ira mRNAs in non-differentiated (NDK) 
are differentiating (DK) cultured human kerdtinocytcs. Results are 
shown in duplicate for each mRNA. 
Furthermore, DK extract contained more IL-lra than 
extract of NK. In contrast, the reverse was observed for 
IL-la and IL-l,8 concentrations which were lower in 
DK. 
Table II 
IL-lra(IL-1 receptor binding assay). IL-la and IL-I/?(EIA) in human 
epidermis, sweat and keratinocyte xtracts 
_- 
Specimen IL-ICY IL-IB Inhibition 
(1120 dilution) (&ml) @/ml) (o/o) 
Buffer NT NT 0 
Epidermis extract 
undepleted 8.69 0.02 100 
depleted CO.01 <O.Ol 75 
Sweat 
undepleted 0.52 <O.Ol 18.24 
depleted co.01 <O.Ol 7.09 
NDK extract 
undepleted 5.31 0.80 100 
depleted 0.03 0.02 84.1 
DK extract 
undepleted I .43 0.33 100 
depleted 0.08 <O.Ol 100 
Supernatant 
undepleted <O.Ol co.01 12.2 
depleted <O.Ol <O.Ol 14.19 
Specimens in Table II were tested before and after depletion of IL-la 
and IL-l/l for inhibitory activity in the IL-I receptor assay. IL-la and 
IL-IB were measured by EIA. NT: non-tested. 
i 
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Fig. 2. IL- I ra in human epidermis and keratinocyte extracts measured 
by IL-l receptor binding assay. EL4-6.1 cells (1x10’) were incubated 
for I h at 4°C with serial dilutions of epidermis (A) NDK (a) or DK 
(:)) extracts. [‘~zI]IL-la was then added (IO 000 cpm/assay) for 4 h at 
4°C. Non-specific binding was determined in the presence of an excess 
of cold hrlL-la and total binding of [‘251]IL-ld was determined in the 
absence of cold hrlL-la. 
3.4. IL-Ira mRNA in drferentiated keratinocytes 
To establish that IL-lra biological activity is consis- 
tent with the level of IL-lra mRNA expressions, IL-lra 
mRNA was analyzed in DK and NDK. IL-lra mRNA 
expression was clearly detected in DK whereas no signal 
was identified in NDK (Fig. 1). This is in accordance 
with the above findings on the IL-lra protein showing 
that DK contained more inhibitory activity than NDK. 
4. DISCUSSION 
We describe the presence of IL-lra using the specific 
inhibition test at the receptor level and the presence of 
IL- 1 mRNA in human epidermis and cultured kerdtino- 
cytes. There was an inverse relationship between the 
level of IL-lra and the amount of IL-la orp since DK 
extract had higher IL-lra and mRNA level than NDK 
and the reverse was found for IL-la or /?. Of interest, 
our data obtained with keratinocytes are similar to 
those obtained in other cell types since IL-l production 
decreases during monocyte differentiation whereas IL- 
lra expression increases during the same process 
[20,21]. In addition, there is evidence that human ma- 
crophages at terminal stage and obtained from bron- 
choalveolar lavage or synovial fluids produce higher 
amounts of IL-lra than blood monocytes and less IL-l 
a or ,!? 122,231. Besides the IL-lra which is secreted 
(sIL-lra) from cells another IL-lra has been identified 
recently which remains intracellular (icIL-lra) [24]. 
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Both are products of same gene, but icIL-lra does not 
contain the leader sequence necessary for secretion. sIL- 
lra is principally produced by monocytes, whereas GIL- 
lra is found only in epithelial cells [24]. Our studies in 
addition clearly demonstrate by the receptor binding 
assay that the biological inhibitory action occurs at the 
receptor level. The presence of intracellular IL-lra in 
normal human epidermis and in keratinocyte xtracts 
of unstimulated epidermal cells could explain why a 
high level of IL-l can also be present in normal skin 
without evidence of inflammation. The ratio of IL-l and 
IL-lra concentrations may be important for the regula- 
tion of keratinocyte differentiation and inflammatory 
processes, and an imbalance between these two pro- 
ducts may lead to deleterious effects. 
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